The knockdown of IGF2BP1 reduced MDM2 protein levels across ovarian cancer cell lines, regardless of TP53 mutation status, increasing IRF1 and TP53 abundance (Supplementary Fig. S4j). This evidence concerns the gene IGF2BP1 and ovarian cancer.